source
- Claris Biotherapeutics raises $118M Series B to advance corneal stem-cell eye dropClaris Biotherapeutics announced a $118 million Series B financing round led by Novo Holdings and supported by several venture firms. The funding will be used to move its lead candidate, CSB-001, i…
- Yarrow goes public while Otsuka receives FDA approval for new ADHD medicationYarrow Bioscience completed a merger that took the company public and will now trade under its own ticker. The firm is developing an anti-TSHR antibody aimed at treating Graves’ disease and the ass…